Tune in for Coverage of the 2022 San Antonio Breast Cancer Symposium

Pharmacy Times®will be onsite in Texas covering the San Antonio Breast Cancer Symposium (SABCS) from December 6 to 10.

SABCS is an annual event cosponsored by the American Association for Cancer Research and UT Health San Antonio’s Mays Cancer Center. Now in its 45th year, the meeting hosts about 10,000 clinicians and scientists from all over the world.

The meeting will include basic, clinical, and translational research and is designed to provide information on the experimental biology, etiology, prevention, diagnosis, and treatment of breast cancer and premalignant breast disease. The program consists of case discussions, forums, poster and slide presentations, and presentations by experts.

Here are sessions to watch for:

• Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes
• Primary results from the randomized phase 2 RIGHT choice trial of premenopausal patients with aggressive HR+/HER2- advanced breast cancer treated with ribociblib + endocrine therapy vs physician’s choice combination chemotherapy
• Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary result of the randomized phase 3 study DESTINY-Breast02
• Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic breast cancer: updated survival results of the randomized, phase 3 study DESTINY-Breast03
• Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase 3 CAPItello-291 trial
• Final overall survival analysis of Monarch 2: a phase 3 trial of abemaciclib plus fulvestrant in patients with hormone receptor-positive, HER2- advanced breast cancer
• GS5-02 GeparOLA trial: paclitaxel + olaparib combination in HER2- and high HRD score – longer-term survival follow-up
• Second interim analysis of overall survival from the TROPiCS-02 phase 3 study of sacituzumab govitecan vs treatment of physician’s choice in patients with HR+/HER2- advanced breast cancer

In addition to these and other sessions, stay tuned for video coverage from the conference.

Follow coverage on PharmacyTimes.com and Pharmacy Times®on social media for exclusive, live coverage and the latest updates from SABCS.